Status:
COMPLETED
Inhaled Furosemide for Transient Tachypnea of Newborn
Lead Sponsor:
Makassed General Hospital
Conditions:
Respiratory Morbidity
Eligibility:
All Genders
1-1 years
Phase:
NA
Brief Summary
This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours fo...
Eligibility Criteria
Inclusion
- Neonates with 34+0-39+0 gestational age
- on the first day of life
- with the clinical diagnosis of Transient Tachypnoea
- need for CPAP \>6 hours to obtain the oxygen saturation \>92%
Exclusion
- Systemic infection
- Intubation and mechanical ventilation before Inclusion in the trail
- Malformation and any other disease with disturb of respiratory system
Key Trial Info
Start Date :
January 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04397991
Start Date
January 2 2020
End Date
August 1 2021
Last Update
August 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Makassed General Hospital
Beirut, Lebanon